Focus on the development of the company to better respond to Customers' expectations
Chief Executive Officer
Peter Burema, Chief Executive Officer, joined NextPharma in June 2014. He has more than 30 years of industry experience, including leadership roles in big pharma, generic drug manufacturing and contract manufacturing. Most recently, Peter served as CEO of Acino, a Swiss-based pharmaceutical company that he led for four years. Prior to that, Peter's experience includes eight years with Ranbaxy Europe Ltd, where he led their Global Pharmaceuticals Business and thirteen years at Bayer. Peter graduated from the St. Olof Business School in the Netherlands.
Chief Mergers and Acquisitions Officer
Alan Dodsworth, Chief Mergers and Acquisitions Officer, joined NextPharma in 2004. Previously, Alan held the positions of Chief Financial Officer (2014-2018) and Executive VP Corporate Development. Prior to joining NextPharma, Alan spent nine years at Ernst & Young, where he was an Assistant Director specialising in corporate finance and transaction support services, leading cross-functional and international teams. Alan is a Chartered Accountant and holds a degree in Economics and History.
Chief Financial Officer
Frank Posnanski, Chief Financial Officer, joined NextPharma in January 2019. Before joining NextPharma, Frank held CFO positions for more than 10 years within national and international finance and controlling departments across a number of companies and industries. From 2011 until 2018, Frank was CFO of TeleColumbus in Berlin, supporting the company from a financial restructuring process through to an IPO and onto the SDAX. He has also worked throughout his career with several Private Equity firms. Frank studied at the University of Dortmund and Zurich and holds a degree in Business & Mathematics.
Chief Operating Officer
Eric Schmidhäuser, Chief Operating Officer, joined NextPharma in July 2016. Eric brings with him over 20 years' experience in the pharmaceutical and automotive industries, with his most recent role being Managing Director for Corden Pharma GmbH. Prior to this, Eric was with Catalent Pharma Solutions for more than 6 years as Managing Director for Catalent Germany Schorndorf GmbH. Eric has held several international management positions in different industries. With this breadth of experience Eric is well placed to support our company growth strategy.
Chief Commercial Officer
Pierre Delavaud, Chief Commercial Officer, joined NextPharma in September 2012 with a strong track record in sales, business development and marketing within the pharmaceutical industry. Prior to joining NextPharma, Pierre held executive sales and business development positions at SkyePharma and spent fourteen years with the Catalent group (and former companies), where he held various senior positions, including Vice President Sales and Business Development Global Pharmaceutical Softgels, Vice President Sales and Marketing Pharmaceutical Technologies and Services Europe, as well as General Manager of a manufacturing site. Pierre holds a PhD in Pharmacy.
Chief Scientific Officer
Kathrin Bartscher, Chief Scientific Officer, joined NextPharma in 2006. She started her career as a project manager in formulation development and over the years has held various positions in the area of product development. In September 2016 she took over the responsibility for the global NextPharma development activities.
Since 2014 she is board member and treasurer of the International Association for Pharmaceutical Technology (APV e.V.) and since 2018 she is an external lecturer for the Master of Industrial Pharmacy program at the Heinrich-Heine-University, Duesseldorf. Kathrin holds a PhD in Pharmaceutical Technology.